Ken Kozuma

Ken Kozuma

Auto-generated profile, based on publicly available information

Ken Kozuma

Teikyo University School of Medicine

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2020 in Cardiovascular Intervention and Therapeutics
Verified
Journal Article
Open access
PDF file
NSNobuaki Suzuki
Nobuaki Suzuki
TATaku Asano
Taku Asano
GNGaku Nakazawa
Gaku Nakazawa
JAJiro Aoki
Jiro Aoki
KTKengo Tanabe
Kengo Tanabe
KKKen Kozuma
Ken Kozuma
Quantitative coronary angiography (QCA) remains to play an important role in clinical trials and post-marketing surveillance related to the safety and efficacy of new PCI devices. In this document, the current standard methodology of QCA is summarized. In addition, its history, recent development and future perspectives are also reviewed.

1 August 1998 in Catheterization and Cardiovascular Diagnosis
Verified
Journal Article
Closed access
PDF file
MYMasao Yamasaki
Masao Yamasaki
KHKazuhiro Hara
Kazuhiro Hara
YIYuji Ikari
Yuji Ikari
NKNobuyuki Kobayashi
Nobuyuki Kobayashi
KKKen Kozuma
Ken Kozuma
TTTsutomu Tamura
Tsutomu Tamura

1 July 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HHHirofumi Hioki
Hirofumi Hioki
YWYusuke Watanabe
Yusuke Watanabe
KKKen Kozuma
Ken Kozuma
MYMasanori Yamamoto
Masanori Yamamoto
TNToru Naganuma
Toru Naganuma
KHKentaro Hayashida
Kentaro Hayashida

23 April 2013 in Cardiovascular Intervention and Therapeutics
Verified
Journal Article
Closed access
PDF file
KKKen Kozuma
Ken Kozuma
TKTakeshi Kimura
Takeshi Kimura
KKKazushige Kadota
Kazushige Kadota
SSSatoru Suwa
Satoru Suwa
KKKazuo Kimura
Kazuo Kimura
KIKeiichi Igarashi
Keiichi Igarashi

3 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
TTTomonori Takahashi
Tomonori Takahashi
KYKyohei Yamaji
Kyohei Yamaji
SKShun Kohsaka
Shun Kohsaka
HIHideki Ishii
Hideki Ishii
YMYuichiro Mori
Yuichiro Mori
JIJ‐PCI Registry Investigators
J‐PCI Registry Investigators
Background: Randomized trials demonstrated that drug‐coated balloon (DCB) was not inferior to drug‐eluting stent (DES) for acute coronary syndrome (ACS). However, generalizability in clinical settings remains unclear. The present study compared the outcomes of DCB and DES strategies in percutaneous coronary intervention for ACS within a nationwide procedure‐based registry. Methods and Results: This was a retrospective analysis of a cohort study from a prospective, nationwide registry between January 2017 and December 2020 in Japan, focusing on patients with ACS who underwent DCB or DES for a single de novo lesion. Patients who required bailout stenting after treatment with DCB were excluded from the analysis. The 1‐year incidence of all‐cause mortality, cardiovascular death, noncardiovascular death, nonfatal ACS, stroke, and major bleeding events was compared. A subgroup analysis included lesion‐based and ST‐elevation myocardial infarction/non‐ST‐elevation ACS stratifications. Among 5212 propensity score–matched patients with ACS, no significant differences were observed in the 1‐year incidence of all‐cause mortality (4.5% versus 4.6%, hazard ratio [HR], 0.92 [95% CI, 0.72–1.19]); cardiovascular death (2.5% versus 2.5%, HR, 0.90 [95% CI, 0.64–1.26]); noncardiovascular death (2.0% versus 2.1%, HR, 0.96 [95% CI, 0.65–1.42]); or nonfatal ACS (1.7% versus 2.0%, HR, 1.04 [95% CI, 0.70–1.54]) between DCB and DES. DCB was associated with a higher incidence of stroke (0.8% versus 0.3%, HR, 2.33 [95% CI, 1.06–5.08]) and lower incidence of major bleeding events (1.4% versus 2.3%, HR, 0.65 [95% CI, 0.43–0.99]); however, these results were not reproduced in the subgroup analysis. Conclusions: The DCB strategy for successfully treated ACS cases achieved similar clinical outcomes to DES after 1 year. Further studies with an extended follow‐up are needed to confirm these results.

25 February 2019 in Circulation Journal
Verified
Journal Article
Open access
PDF file
MNMasato Nakamura
Masato Nakamura
KKKen Kozuma
Ken Kozuma
TKTakanari Kitazono
Takanari Kitazono
TITomoko Iizuka
Tomoko Iizuka
TSToru Sekine
Toru Sekine
SKSeiji Kogure
Seiji Kogure
Background: A unique dose of prasugrel has been approved exclusively for Japanese patients, but real-world data for prasugrel at that dose in patients with ischemic heart disease (IHD) are limited. Therefore, large-scale, real-world data are needed. Methods and Results: A 2-year observational study of Japanese patients with IHD undergoing percutaneous coronary intervention and being treated with prasugrel to evaluate safety and effectiveness. This report is an interim analysis of data from case report forms (CRFs) after 3 months. CRFs were collected from 4,270 patients, 4,157 of whom were eligible for the safety and effectiveness analysis sets (mean age, 68.3 years; male, 76.5%). The median treatment period was 112 days, and 92.3% of patients continued treatment with prasugrel. The incidence of non-coronary artery bypass grafting-related bleeding adverse events (AEs) was 3.1%, of which Thrombolysis in Myocardial Infarction (TIMI) major and minor bleeding accounted for 0.5% and 0.6%, respectively. The most common bleeding AEs were gastrointestinal disorders, which accounted for 43.2% of the sum of “TIMI major and minor bleeding AEs”. The incidence of major adverse cardiovascular events (MACE) was 1.0%, and the cumulative incidence of MACE was 1.4%. The incidence of stent thrombosis was 0.2%. Conclusions: Interim study results indicated that prasugrel was safe and effective during the early phase of treatment in Japanese patients with IHD in real-world clinical settings.